PYC Therapeutics (ASX:PYC) to Present PKD Program Data at ASN Conference

Aditi Sarkar

07 October 2026 05:08 PM AEDT

PYC Therapeutics (ASX:PYC) to Present PKD Program Data at ASN Conference

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

PYC will present PYC-003 data at the ASN conference in Denver on 22 October 2026.
Treated patients showed a 46% increase in urinary PC1 protein versus baseline.
Kidney Volume showed apparent stabilisation at 3 months compared with historical progression.
The company cautions that the data comes from a small number of patients over a short period.

PYC Therapeutics Limited (ASX:PYC) announced on 7 October 2026 that it will present data from its Polycystic Kidney Disease (PKD) program at the American Society of Nephrology (ASN) conference in Denver, Colorado, on 22 October 2026. The data relates to PYC-003, which is designed to address the underlying cause of PKD in patients with PKD1 gene mutations.

Urinary PC1 Protein Results

In single-dose Phase 1a/1b studies, treated patients showed a 46% increase in urinary PC1 protein compared with baseline (p<0.05).

The data was pooled from seven patients, with three receiving 1.2 mg/kg and four receiving 2.4 mg/kg.

Total Kidney Volume Observations

Total kidney volume was measured three months after treatment in 18 patients. The results showed apparent stabilisation compared with historical rates of progression.

For comparison, untreated patients in Mayo Imaging Class C, D and E have shown estimated kidney volume growth of 6.2% a year, based on data from the TEMPO 3:4, CRISP and HALT-PKD A trials.

Caveats and Development Pathway

PYC stressed that the exploratory data was generated in a small number of patients over a short period and needs to be reproduced in larger, longer studies before conclusions can be drawn about therapeutic impact.

Data from the Phase 1b Multiple Ascending Dose study and the Open-Label Extension study is expected during 2027. PYC plans to progress towards a registrational combined Phase 2/3 trial following regulatory alignment.

Key Takeaways

PYC will present PYC-003 data at the ASN conference on 22 October 2026.
Urinary PC1 protein rose 46% from baseline in seven treated patients.
Kidney volume appeared stable at 3 months in 18 patients.
Further MAD and extension study data is expected in 2027.

FAQs

Q: What is PYC-003?

A:A drug candidate designed to address the underlying cause of polycystic kidney disease in patients with PKD1 mutations.

Q: When and where will the data be presented?

A:At the ASN conference in Denver, Colorado, on 22 October 2026.

Q: What did urinary PC1 results show?

A:A 46% increase versus baseline in seven treated patients.

Q: Are the results conclusive?

A:No. The company says the data is exploratory and needs confirmation in larger, longer studies.

Q: What data is expected next?

A:Phase 1b MAD and Open-Label Extension study data during 2027.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.